2016
RARE-39. INTRAVASCULAR LYMPHOMA AFFECTING THE CENTRAL NERVOUS SYSTEM: FEATURES AND OUTCOMES IN A CASE SERIES OF THE PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG)
Zukas A, Bennani N, Chou C, Johnston P, O’Neill B, Nijland M, Batchelor T, Nayak L, Mrugala M, Low J, Omuro A, Ferreri A, Nishikawa R, Mishima K, Fox C, Wilson W, Houillier C, Chamberlain M, Schiff D. RARE-39. INTRAVASCULAR LYMPHOMA AFFECTING THE CENTRAL NERVOUS SYSTEM: FEATURES AND OUTCOMES IN A CASE SERIES OF THE PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG). Neuro-Oncology 2016, 18: vi168-vi168. DOI: 10.1093/neuonc/now212.702.Peer-Reviewed Original ResearchCentral nervous systemIntravascular lymphomaOne-year survivalCase seriesCombination therapyTreatment outcomesEastern Cooperative Oncology Group performance statusNervous systemCommon first-line treatmentMedian progression-free survivalHigh-dose methotrexate therapyLarge B-cell typePrimary central nervous systemLarge B-cell lymphomaHigh-dose methotrexatePercent of patientsPoor functional statusFirst-line treatmentPrimary CNS lymphomaProgression-free survivalStroke-like symptomsMean diagnostic delayRetrospective case seriesTime of diagnosisTime of presentation
2013
Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG).
Kaley T, Pentsova E, Omuro A, Mellinghoff I, Nolan C, Gavrilovic I, DeAngelis L, Lacouture M, Holland E, Lassman A. Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG). Journal Of Clinical Oncology 2013, 31: 2095-2095. DOI: 10.1200/jco.2013.31.15_suppl.2095.Peer-Reviewed Original ResearchRecurrent malignant gliomaPhase I trialMalignant gliomasI trialDose level 3Dose level 7Dose of temsirolimusMedian age 52Progressive malignant gliomaSynergistic anti-tumor effectPI3K/Akt/mTOR signalingAkt/mTOR SignalingMTOR inhibitor temsirolimusAnti-tumor effectsPotential therapeutic targetKPS 80Prior RTPrior therapyLimiting toxicitiesIntracerebral hemorrhageCombined therapyCombination therapyPreclinical dataLung infectionCell cycle arrest